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Mapping lung cancer epithelial-mesenchymal
transition states and trajectories with
single-cell resolution
Loukia G. Karacosta1,2, Benedict Anchang1,2, Nikolaos Ignatiadis3, Samuel C. Kimmey 4, Jalen A. Benson5,
Joseph B. Shrager5, Robert Tibshirani1,3, Sean C. Bendall 4,6 & Sylvia K. Plevritis1,2,6*
Elucidating the spectrum of epithelial-mesenchymal transition (EMT) and mesenchymal-
epithelial transition (MET) states in clinical samples promises insights on cancer progression
and drug resistance. Using mass cytometry time-course analysis, we resolve lung cancer
EMT states through TGFβ-treatment and identify, through TGFβ-withdrawal, a distinct MET
state. We demonstrate significant differences between EMT and MET trajectories using a
computational tool (TRACER) for reconstructing trajectories between cell states. In addition,
we construct a lung cancer reference map of EMT and MET states referred to as the EMT-
MET PHENOtypic STAte MaP (PHENOSTAMP). Using a neural net algorithm, we project
clinical samples onto the EMT-MET PHENOSTAMP to characterize their phenotypic profile
with single-cell resolution in terms of our in vitro EMT-MET analysis. In summary, we provide
a framework to phenotypically characterize clinical samples in the context of in vitro EMT-
MET findings which could help assess clinical relevance of EMT in cancer in future studies.
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Malignant cells often hijack biological processes that areutilized by their normal cell counterparts1. One exam-ple is the epithelial–mesenchymal transition (EMT), a
developmental program critical to embryogenesis and wound
healing2,3. During EMT, epithelial cells undergo dramatic bio-
chemical and morphological changes and acquire migratory and
stem-like traits4. EMT is a dynamic process and under specific
conditions is reversible (mesenchymal–epithelial transition,
MET), highlighting a phenotypic plasticity that has been observed
in both normal and malignant cells3.
The clinical significance of EMT in cancer is well documented,
although controversial5. Mesenchymal signatures are indicators
of poor prognosis in various adenocarcinomas, including lung6,7.
In addition, several studies have demonstrated the role of EMT in
drug response and resistance8,9, offering evidence that EMT sig-
natures can be of therapeutic value. However, because most of
these cancer-related EMT studies are based on bulk gene
expression data from clinical specimens, it is often unclear whe-
ther clinical EMT signatures originate from mesenchymal
malignant cells as opposed to tumor stromal cells (e.g., fibro-
blasts), which express EMT canonical markers. Furthermore,
malignant cells with a purely mesenchymal phenotype are con-
sidered rare, with a small chance of clinical observation10; thus,
the existence of such malignant cells is debated.
Adding to the complexity in understanding the clinical sig-
nificance of EMT is the recognition that EMT is not a binary
process (strictly defined by epithelial and mesenchymal states),
but instead a spectrum of states where transitioning cells exhibit
partial EMT phenotypes with both epithelial and mesenchymal
features. Partial EMT phenotypes have been observed in clinical
cancer specimens and negatively correlate with survival9,11, but
are poorly understood. Recent studies have attempted to better
define EMT states using single-cell approaches; however, they
were primarily focused on preclinical models or clinical sam-
ples without bridging the two. Pastushenko et al.12 demon-
strated the existence of partial EMT states in mammary and
skin cancer by examining a large number of surface markers
with flow cytometry and single-cell RNA-sequencing (sc-
RNAseq). Gonzalez et al.13 identified partial EMT states in
ovarian cancer specimens with mass cytometry. While these
studies provide important insights, they did not directly relate
their findings to EMT states that have been well characterized
in preclinical in vitro reference models. On the other hand,
mass cytometry was used to study drug perturbations on tumor
growth factor-β (TGFβ)-induced EMT in mouse epithelial
cancer cells14, and sc-RNAseq was used to study TGFβ-induced
EMT in human breast epithelial cells15; however, neither of
these studies provided a means to assess the clinical relevance of
their respective findings.
In this study, we use high-dimensional single-cell analysis to
identify and characterize EMT states observed in lung cancer
clinical specimens in terms of the spectrum of states observed in
well-established lung cancer cell lines. Specifically, through mass
cytometry time-course analysis of TGFβ-modulated EMT and
MET in lung cancer cells, we computationally define eight EMT
and MET states with which we create an EMT–MET PHENO-
typic STAte MaP (PHENOSTAMP). In addition, we develop and
apply the TRAjectory of CElls Reconstruction (TRACER) algo-
rithm, which compares state transitions in EMT and MET.
Finally, we develop and apply a machine learning algorithm to
project malignant cells from clinical samples onto the EMT–MET
PHENOSTAMP in order to assess clinically relevant EMT and
MET states in terms of our in vitro time-course analysis. Use of
the EMT–MET PHENOSTAMP, informed by our trajectory
analysis, provides a means to distinguish whether cells are
undergoing EMT or MET and thereby has the potential to
identify EMT- or MET-related phenotypic cell properties such as
state-specific differential drug sensitivities9,16.
Results
Identifying canonical EMT states in lung cancer cells. To
identify EMT states in lung cancer cells, we used TGFβ for EMT
induction. First, we examined TGFβ responsiveness in three
non-small-cell lung carcinoma (NSCLC) cell lines (HCC827,
A549, H3255) towards bulk expression of widely accepted EMT
markers (E-Cadherin, Vimentin, CD442,4,17) (Fig. 1a). A549
cells displayed partial EMT (pEMT) characteristics before
TGFβ treatment (basal co-expression of epithelial (E-Cadherin)
and mesenchymal (Vimentin, CD44) markers). With treatment,
A549 cells exhibited loss of E-Cadherin and acquired
mesenchymal-like morphology (Fig. 1a, Supplementary Fig. 1).
H3255 cells exhibited strong basal epithelial features and
retained their epithelial morphology and protein expression
with TGFβ treatment without displaying EMT-related changes
(Fig. 1a, Supplementary Fig. 1). The HCC827 cell line displayed
epithelial features at basal conditions and underwent dramatic
EMT marker and morphology changes with treatment (Fig. 1a,
b), and hence was chosen as the exemplary cell line for our
EMT studies.
Morphological heterogeneity was observed in HCC827 cells
during EMT, as evidenced by confocal imaging (Fig. 1b).
Intriguingly, cells that were not incorporated in epithelial islands
expressed Vimentin even in the absence of exogenous TGFβ,
demonstrating that cell density likely affects EMT status (Fig. 1b
(b)). This finding was corroborated when we examined EMT in
HCC827 cells with flow cytometry under varying seeding
conditions that controlled confluency (Supplementary Figs. 1
and 2) and is consistent with previous reports for normal
epithelial cells18. Transition was also reflected by CD44 and CD24
gradual changes (stemness markers often used in breast cancer
EMT studies), patterning four readily observed gating popula-
tions (Supplementary Fig. 1). These subpopulations—referred to
as “states”—were characterized by progressive increase of CD44
and decrease of CD24 in only a small subset of cells (CD44hi/
CD24lo), which represents a phenotypic state regarded as cancer
stem cell-like (CSC-like)4,19.
To adequately capture EMT states, we optimized a TGFβ time-
course during which we kept confluency consistent by re-seeding
cells at each experimental time-point. Cells efficiently underwent
EMT within 10 days of TGFβ treatment towards morphology
(Fig.1c, top images) and changes in E-Cadherin, Vimentin, CD44
and CD24 expression (Fig. 1c, biaxial plots). Since these markers are
commonly used for EMT characterization, we refer to these four
states, as canonical EMT states. As CD44/CD24 biaxial plots gave
four well-separated populations for manual gating (Supplementary
Fig. 1), we used these to assess E-Cadherin/Vimentin expression
(Fig. 1c, bottom plots) and designated the four canonical states into
(i) an epithelial (E) (E-Cadherin+/Vimentin−), (ii) a pEMT (E-
Cadherin+/Vimentin+), (iii) a mixed pEMT/M (E-Cadherin+/
Vimentin+, E-Cadherin−/Vimentin+), and (iv) a small mesench-
ymal CSC-like state (E-Cadherin−/Vimentin+/CD44hi/CD24lo),
denoted here as M* (Fig. 1d, Supplementary Fig. 1). Each state’s
occupancy with time is depicted in Fig. 1e. Mean fold expression of
the four markers recapitulated the observed changes towards both
control conditions with time and towards the E state when
examined in each state separately (Fig. 1f). Unexpectedly, E-
Cadherin transiently increased in the pEMT state. We speculate this
may be due to increased surface interactions between cells of
enlarged size observed during initial EMT stages (Supplementary
Fig. 1). We also observed time-dependent changes in the EMT
transcription factor Twist20 (Fig.1f). Specifically, Twist expression
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was highest in the pEMT state and lowest in the M* state (Fig. 1f,
right).
Phenotyping canonical EMT states with mass cytometry.
Manual gating based on the expression of just four markers was
helpful for our initial assessment of canonical EMT states, albeit
this approach does not fully characterize the heterogeneity of
these states. For a more thorough characterization of the cano-
nical EMT states, we performed a mass cytometry time-course
experiment on HCC827 cells where TGFβ was added for
10 days and subsequently withdrawn to observe EMT and MET,
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E-Cadherin
Vimentin
CD44
GAPDH
2
1
3
4
1
2
4 3
105
104
103
102
–102
105104103102–102
105104103102–102
105104103102–102
a
a b
c d
0
10
20
30
40
50
60
70
80
90
100
Ctrl 2d 6d 10d
E
pEMT
pEMT/M
M*
1: “E” 2: “pEMT” 3: “pEMT/M” 4: “M*” (CD44hi/CD24low)
E-
Ca
dh
er
in
CD
44
Vimentin
CD24
Ctrl 2d TGFβ 6d TGFβ 10d TGFβ
Ctrl TGFβ Ctrl TGFβ Ctrl TGFβ
E-
Ca
dh
er
in
Vimentin
E-Cadherin
Vimentin
CD44
CD24
Twist
Ctrl 2d 6d 10d E pEMT pEMT/M M*
Treatment States
Max fold
decrease
Max fold
increase
Fold change vs.
Ctrl & E
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.68
1.5
1.35
–0.08
0.0
0.26
2.29
1.94
–0.02
–0.12
–0.7
2.71
2.67
–0.27
–0.34
0.34
0.8
1.35
0.08
0.3
–1.76
1.36
3.35
–0.43
0.06
–2.46
0.89
2.65
–1.44
–0.66
Days
%
 o
f t
ot
al
 #
 c
el
ls 
pe
r c
on
di
tio
n
b
c
d
e f
~135 kDa
~57 kDa
~80 kDa
~37 kDa
105
104
103
102
–102
105
104
103
102
–102
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13441-6 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:5587 | https://doi.org/10.1038/s41467-019-13441-6 | www.nature.com/naturecommunications 3
respectively (Fig. 2a). For optimal confluency conditions, at each
time-point, cells were collected for both mass cytometry analysis
and re-seeding for subsequent time-points. In total, 28 markers
were chosen to characterize EMT states as well as proliferative,
signaling, and apoptotic cell status (Fig. 2a, Supplementary
Table 1). The four canonical EMT states were reproduced on
mass cytometry (Fig. 2b, Supplementary Figs. 2 and 3) as were the
fold expression trends of all previously discussed markers (Fig. 2c,
Supplementary Fig. 3). Upon TGFβ withdrawal, a proportion of
cells that had undergone EMT returned to an epithelial state, an
observation supported by canonical EMT marker expression and
morphological assessment (Fig. 2b, c).
Mass cytometry enabled us to examine dynamic changes of
additional markers (Fig. 2d, Supplementary Fig. 3). Keratins and
other epithelial cell surface markers (e.g., MUC1, TROP2)
showed expected decreases during EMT and subsequent return
to basal levels following MET. Most signaling and proliferative
markers rapidly increased in expression on day 2 under TGFβ
treatment, and subsequently decreased by day 10 in TGFβ.
Decreased expression of these markers was sustained during the
first 2 days of withdrawal, time-points for which M and M* cells
were at highest numbers. Specifically, this pattern was observed
for pSMAD2/3, a key TGFβ signaling molecule21, as well as for
pEGFR (epidermal growth factor receptor) and pS6, suggesting
that signaling is downregulated in the M state. Notably, pEGFR
and pS6 were lowest in the CSC-like M* cells (Supplementary
Fig. 3), corroborating studies that have associated EMT with
tyrosine kinase inhibitor (TKI) resistance8 and low p-mTOR
(mammalian target of rapamycin) activity with stem cell
maintenance22. We also observed an increase of PD-L1 during
EMT, substantiating reports that link EMT with tumor immune
evasion23. Among the measured EMT transcription factors, apart
from the transient activation of Twist, we did not detect
significant Snail or Slug expression. However, Oct3/4 and Nanog
showed a substantial increase throughout the EMT time-course,
consistent with a lung adenocarcinoma study where co-
expression of Oct3/4 and Nanog were found to be critical for
EMT24.
Defining computationally derived EMT and MET states. Our
above-described assessment of EMT states showed that at least at
the protein level cells seem to transition through a spectrum of
overlapping phenotypes. Given the high dimensionality of our
data, we applied unsupervised cluster analysis to computationally
derive well-defined EMT and MET states. From hereon, the
previously described canonical EMT states hold no particular
significance, but will be related to computationally derived EMT
states. We first applied CCAST, a clustering algorithm that
applies non-parametric tests to partition the data in the form of a
decision tree on the pooled mass cytometry data across all time-
points25. Clustering markers E-Cadherin, Vimentin, CD44,
CD24, MUC1, and Twist were selected based on principal com-
ponent analysis (PCA) of the data (PCA and principal compo-
nent loadings shown in Supplementary Table 2 and
Supplementary Fig. 4, respectively). CCAST identified eight most
prominent states, each state having ≥1% of total number of cells
analyzed. The CCAST decision tree and downstream analyses, as
well as the relation between the computationally derived with the
four canonical EMT states are shown in Supplementary Figs. 5
and 6.
Heatmaps of the six clustering markers within each of the eight
states revealed minimal within-state marker heterogeneity
compared to between-state marker heterogeneity (Fig. 3a). We
labeled the derived EMT and MET states based on the expression
profile (e.g., E-Cadherin+/Vimentin− in epithelial states, E-
Cadherin+/Vimentin+ in pEMT states, etc.) and respective time-
course pattern, which helped distinguish, for example, mesench-
ymal cells from cells undergoing MET (i.e., cells appearing after
TGFβ removal). Specifically, we identified three E states (E1, E2,
E3), three pEMT states (pEMT1, pEMT2, pEMT3), one M state,
and one MET state (Fig. 3b). States E1, E2, and E3 displayed low
expression of Vimentin and CD44, but varying degrees of E-
Cadherin, CD24, and MUC1 expression. All E states were highest
in numbers at time 0 and dramatically decreased with TGFβ
treatment; only E1 and E2 rebounded following TGFβ with-
drawal. States pEMT1, pEMT2, and pEMT3 co-expressed E-
Cadherin and Vimentin, consistent with a pEMT phenotype.
pEMT2 and pEMT3 specifically included a subgroup of Twist+
cells (Fig. 3a, boxed regions). All pEMT states emerged upon
TGFβ treatment, decreased with continued TGFβ treatment, and
with the exception of pEMT3, transiently re-emerged during
withdrawal. State M was characterized by loss of epithelial
markers (E-Cadherin, MUC1), and high Vimentin and CD44
expression, and was highest in numbers at day 10 in TGFβ.
Interestingly, Twist+ cells were not detected within this state,
confirming a study that found that CSC-like properties arise
following transient Twist activation during EMT26. Although our
analysis did not distinguish CSC-like cells as a separate cluster,
interrogation of other markers in cells expressing the lowest
CD24 levels (e.g., pS6) helped us define the CSC-like cells within
the M state (M*, Supplementary Fig. 6). State MET, perhaps most
interesting in our analysis, peaked upon withdrawal specifically,
representing cells that had perhaps initiated MET. The MET state
differed from the M state in only one of six clustering markers,
exhibiting increased MUC1 expression. Of note, MUC1 has been
reported to be a MET marker in nephrogenesis27, corroborating
our findings here in lung cancer. MET cells also expressed higher
Fig. 1 Identifying canonical EMT states in lung cancer cells through TGFβ time-course analysis. a Immunoblot of EMT markers in the presence or
absence of TGFβ in three NSCLC cell lines (2 week treatment in HCC827 and H3255 cells, 1 week treatment in A549 cells). b Representative confocal
images of HCC827 cells stained for E-Cadherin (red) and Vimentin (green) in the absence (a, b) or presence of TGFβ (c, d) for 10 days. Magnification ×40,
scale bar 20 μm. White dotted arrows indicate cells that show loss of E-Cadherin and gain of Vimentin expression in untreated conditions. White solid
arrows show enlarged cells on the periphery of epithelial islands that have acquired a pEMT phenotype (E-Cadherin+/Vimentin+); blue and red solid
arrows indicate either enlarged and elongated or small and spindle-shaped cells that have acquired mesenchymal phenotypes (E-Cadherin−/Vimentin+).
c Representative images of HCC827 cells treated with TGFβ (5 ng/mL) for 2, 6, and 10 days under continuous re-seeding conditions (see also
Supplementary Figs. 1 and 2 and Methods). Magnification ×10, scale bar 200 μm. Below each image are shown respective E-Cadherin/Vimentin and
CD44/CD24 flow cytometry plots. Arrows indicate changes in marker expression during EMT and numbers 1–4 designate the identified canonical EMT
states, respectively: Epithelial (E), pEMT, pEMT/Mesenchymal (M), and M* (characterized by CD44hi/CD24lo, CSC-like cells). d Color-coded gated EMT
canonical states depicted on E-Cadherin/Vimentin flow cytometry plots per experimental condition (see also Supplementary Fig. 1). e EMT state dynamics
during TGFβ time course. Color-coded EMT states were calculated and depicted as % of total number of cells at each experimental time-point. f Heatmap
summary of EMT marker fold (arsinh) changes relative to control condition when analyzed in all cells (left) and relative to the E state when analyzed in the
four canonical EMT states individually at the 10-day TGFβ time-point (right). Source Data are provided as a Source Data file.
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Fig. 2 Mass cytometry time-series analysis offers deep single-cell resolution of canonical EMT states. a Workflow schematic of cell culture conditions
for TGFβ time-course (addition and withdrawal (W) time-points) and mass cytometry analysis. Arrows indicate times at which cells were collected for
both analysis and re-seeding for the remaining time-points (see also Supplementary Table 1, Figs. 2 and 3, and Methods). b Representative images of
HCC827 cells at each time-point (magnification ×10, scale bar 200 μm) with respective E-Cadherin/Vimentin and CD44/CD24 mass cytometry plots
shown below. Arrows indicate the previously observed canonical EMT marker changes and states, respectively. c Histogram overlays illustrating EMT
marker expression distributions in HCC827 cells undergoing EMT and MET. On the right, a heatmap summary of the canonical EMT marker fold (arsinh)
changes relative to state E when analyzed in the four EMT states individually at the 10-day TGFβ time-point. d Additional marker distributions in HCC827
cells undergoing EMT and MET (see Supplementary Fig. 3 for remaining markers and an independent biological replicate experiment).
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levels of the epithelial markers TROP2 and cytokeratin 8
compared to M cells, confirming that these cells have initiated
MET (Supplementary Table 3). Ordering the states according to
temporal pattern and phenotype provided a quantitative
examination of the expression changes of the six clustering
markers (Fig. 3c). Similar results were observed in an indepen-
dent biological replicate experiment (Supplementary Fig. 6).
To better visualize the phenotypic profiles and dynamic
changes of the derived EMT and MET states, we constructed a
force-directed layout (FDL) of the high-dimensional data using
Vortex28 (Fig. 3d, Supplementary Fig. 6). Cells from each of the
eight states were added sequentially per time-point and data
were visualized in terms of time (Fig. 3d, left), or state (Fig. 3d,
right). Thus, we were able to visually decipher the EMT from the
MET trajectory, and identify states that appeared to be transient
(e.g., pEMT3), or revisited during (e.g., pEMT1, pEMT2), or at
MET completion (e.g., E1, E2). Strikingly, MET state appeared to
be specific to the withdrawal time-points, supporting studies
proposing that the MET trajectory differs from the EMT one29,30.
Expression profiles of all markers are depicted in FDLs in Fig. 3e
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Fig. 3 Unsupervised analysis of mass cytometry data reveals computationally derived EMT and MET states. a Heatmaps depicting the expression of the
six clustering markers in each cell (E-Cadherin, Vimentin, CD44, CD24, Twist, and MUC1) per computationally derived EMT and MET state (normalized
global expression). Shown are the most prominent in number states that resulted from the CCAST algorithm performed on pooled mass cytometry
HCC827 data. Dotted boxed regions illustrate subpopulations of Twist+ pEMT cells (see also Supplementary Fig. 6). b EMT and MET state dynamics. Each
graph corresponds to the state heatmap above. States were calculated and depicted as % of total number of cells at each experimental time-point.
c Graphs illustrating mean expression of the six clustering markers in EMT and MET states. Bars represent standard deviation (s.d.) of each marker within
each downsampled state (E1 cells n= 2394, E2 cells n= 3284, E3 cells n= 1316, pEMT1 cells n= 3359, pEMT2 cells n= 2943, pEMT3 cells n= 2663,
M cells n= 9609, MET cells n= 3498). d Time-resolved force-directed (FDL) layout of mass cytometry time-course data (left) and respective EMT and
MET state annotations (right). Dotted area depicts subpopulation of M cells that exhibit CSC-like phenotypic characteristics (CD44hi/CD24lo, M*).
e Time-resolved FDL layouts colored by protein expression of indicated markers (arsinh transformed data). See Supplementary Fig. 6 for remaining
markers and analysis of an independent biological replicate experiment. Source Data are provided as a Source Data file.
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and Supplementary Fig. 6. FDLs revealed that Twist+ cells are
characterized by high expression of cytokeratins 7 and 8,
signaling molecules (e.g., pSMAD2/3, pEGFR), and transcription
factors Oct3/4 and Nanog. High cytokeratin expression corrobo-
rates studies showing that Twist+ cells constitute a specific type of
epithelial cells31. On the other hand, cells in the M state are
characterized by low signaling and proliferative profiles, a finding
that agrees with our earlier observations (Fig. 2, Supplementary
Fig. 3) and published reports22,32.
Constructing an EMT–MET PHENOtypic STAte MaP. Apart
from visualizing the phenotypic, time-dependent properties of
EMT and MET states, our goal was to construct an EMT–MET
PHENOtypic STAte MaP (PHENOSTAMP) for inferring the
presence of the eight EMT and MET states in NSCLC clinical
specimens with single-cell resolution. First, we generated a two-
dimensional (2D) t-distributed stochastic neighbor embedding (t-
SNE) projection of the eight states. Given that the EMT and MET
states showed considerable phenotypic overlap on the t-SNE
space, we employed Voronoi and Convex Hull analysis33 to
achieve density-driven segmentation of the t-SNE landscape; each
segment corresponding to an identified EMT/MET phenotypic
state at its peak during our time-course analysis (Fig. 4a, b and
Supplementary Figs. 5 and 7). Analysis of cell density over time
on the EMT–MET PHENOSTAMP confirmed our previous
assessment that the MET trajectory differs from the EMT one and
is specifically characterized by the appearance of the MET state at
the 2-day withdrawal time-point (Fig. 4c). However, it also
revealed the possibility that cells that belong to pEMT states
exhibit plasticity that enables them to follow the same state tra-
jectory back to E states under withdrawal. This observation is
heuristically demonstrated in a density-driven preliminary
assessment of transitions within the 2D map, depicted in a con-
ceptual schematic model (Fig. 4d). When we applied the com-
putational tool Slingshot34 to these data, it independently
resolved the trajectory that involves the appearance of the MET
state during withdrawal (Supplementary Fig. 7). However, it did
not fully capture our empirical observations of likely state tran-
sitions, given that as most pseudotime algorithms, it forces cells
onto a deterministic trajectory derived from prior knowledge.
TRACER analysis identifies distinct EMT and MET trajec-
tories. Given that EMT is likely characterized by plasticity among
states and not a single trajectory, we developed a trajectory
algorithm, TRACER (Supplementary Fig. 5 and Methods), that
does not rely on pseudotime assumptions. We assumed that EMT
and MET are classical Markov processes35 with transition prob-
abilities that are constant between the states within EMT and
MET, but can differ when comparing the two. We applied our
model separately for the EMT and MET time-points and, through
bootstrap analysis, we generated a distribution of transition
probabilities between states under EMT and MET, as shown in
Fig. 4e. The resulting medoid networks for EMT and MET are
provided in Fig. 4f. The bootstrap analysis shows less non-zero
state transition probabilities under MET compared to EMT,
demonstrating that the transition between M and MET states is
unique to MET. Our analysis also shows that cells in the iden-
tified states may transverse a set of possible EMT trajectories
representing perhaps differing state kinetics (differentially
weighted EMT transition probabilities, Fig. 4f). These results
demonstrate statistically significant differences between EMT and
MET trajectories as well as bi-directionality (plasticity) between
certain states (e.g., the transition probability from pEMT1 to
pEMT2 during EMT is 0.33, whereas during MET the transition
from pEMT2 to pEMT1 is 0.27).
Projection of NSCLC cell lines onto the EMT–MET PHE-
NOSTAMP. Given the wide range of phenotypic, and pre-
sumably functional, EMT–MET states across NSCLC cell lines,
we tested whether our EMT–MET PHENOSTAMP could serve as
a reference to reconcile known heterogeneity between cell lines
and experiments. To project independent samples onto PHE-
NOSTAMP, we trained a neural net algorithm36,37 that predicts
the bivariate t-SNE outputs of our EMT–MET PHENOSTAMP in
terms of the selected six clustering markers (Supplementary Fig. 5
and Methods). We verified the performance of the projection
using lung cancer cell lines with known features. First, we pro-
jected independently analyzed TGFβ HCC827 samples, and these
matched previously observed mappings (Fig. 5a, left). Next, we
projected two NSCLC cell lines analyzed with mass cytometry
(A549, H3255), given that we had prior knowledge of their EMT
status (Fig. 1a). In agreement with our previous findings, A549
cells mapped onto pEMT and M regions in control conditions
and extended into the M region upon TGFβ treatment (Fig. 5a,
middle, Supplementary Fig. 8), and H3255 cells mapped mostly
on E, and to a lesser degree on pEMT1 regions, with minimal
changes upon TGFβ treatment (Fig. 5a, right, Supplementary
Fig. 8). These map projections were consistent with morpholo-
gical assessment and respective E-Cadherin/Vimentin and CD44/
CD24 expression profiles (Fig. 5b, c).
Phenotyping NSCLC clinical samples with EMT–MET PHE-
NOSTAMP. We proceeded to determine the spectrum of EMT
and MET states in NSCLC clinical specimens with single-cell
resolution by projecting them onto the EMT–MET PHENOS-
TAMP. Five fresh NSCLC adenocarcinoma samples were
obtained immediately after patient resection under Institutional
Review Board (IRB) approval and underwent immediate dis-
sociation for single-cell suspension. For mass cytometry analysis,
we used the antibody panel developed for our time-course ana-
lysis, augmented with antibodies to sort out immune (CD45+),
endothelial (CD31+), and stromal fibroblast (FAP+) popula-
tions13. Thus, we were able to discriminate immune, endothelial,
and stromal cells from cells that were of varying levels of cyto-
keratins 7 and 8 that were negative for CD45, CD31, and FAP
(Supplementary Figs. 2 and 9). The specimens harbored different
mutations and differentiation status (Fig. 6, Supplementary
Table 4). We validated both the mass cytometry run and pro-
jection, by analyzing in parallel independent HCC827 samples as
a control (Supplementary Fig. 9). Upon projection, all clinical
specimens showed the presence of a variety of EMT states that
agreed with their respective E-Cadherin/Vimentin expression
profiles (Fig. 6, Supplementary Fig. 9). Reassuringly, given the
single-cell resolution of the mapping function, each clinical
sample demonstrated a continuous sweep of EMT states, as
opposed to occupying disjoint regions. Case nos. 1, 2, and 3 (all
EGFR mutated) mapped primarily onto E regions with some
extent into the pEMT1 regions, and expressed, as expected,
higher pEGFR levels (Supplementary Fig. 10). This mapping is
consistent with EGFR-mutated cell lines HCC827 and H3255 in
basal conditions and confirmed by morphological assessment
(Supplementary Fig. 9). Case No. 3, harboring an additional TP53
mutation, broadly extended into the pEMT regions, with a small
fraction of cells in the M and MET regions. Case nos. 4 and 5,
harboring TP53 and KRAS mutations, respectively, showed the
most pEMT features, occupying pEMT2 and pEMT3 regions
(and to a lesser degree M), reassuringly similar to A549 cells that
are also KRAS mutated (Fig. 5). Interestingly, case nos. 4 and 5, in
comparison to case nos. 1–3, were graded as poorly differentiated
and showed higher levels of immune infiltration (Fig. 6, Sup-
plementary Fig. 9), suggesting the association of these clinical
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features with specific EMT states. While a larger sample size is
necessary to solidify conclusions, these results are consistent with
studies reporting correlations between NSCLC mutations and
immune infiltration with EMT status23,38,39. Overall, we show
that our EMT–MET PHENOSTAMP can be utilized to score and
interpret clinical specimen data towards EMT and MET state
heterogeneity and that similar approaches can be extended to
phenotyping a range of cellular processes that involve cell state
transitions.
Discussion
Elucidating what is believed to be a spectrum of EMT–MET states
with single-cell resolution promises insights on their role in
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cancer. We provide an integrated experimental–computational
framework to define discrete lung cancer EMT and MET states
and assess their clinical relevance. First, we identified EMT and
MET states leveraging high-dimensional mass cytometry time-
course analyses of lung cancer cell lines undergoing EMT and
MET through TGFβ treatment and withdrawal. We then con-
structed EMT–MET PHENOSTAMP, and using a neural
net algorithm, we projected clinical samples onto the map to
evaluate their EMT and MET state profile with single-cell reso-
lution. This integrated approach provides in vitro insights on
EMT–MET biology and establishes a framework to translate
in vitro observations to clinical samples.
The EMT process has been described as a spectrum of inter-
mediate phenotypic states40–42, and this is something we observe
when we interrogate transitioning cells towards their protein
expression changes. Cells appear to occupy a continuum of
phenotypic space (biaxial plots in Figs. 1 and 2), making it dif-
ficult to discern discrete EMT populations. This is also evident by
our clinical specimen projections (Fig. 6) as these occupy con-
nected regions on our EMT–MET PHENOSTAMP. Other
investigators have defined a discrete number of EMT states in
various systems, albeit using either bulk gene expression data or
surface-only protein markers12,17. In this study, we used CCAST
analysis of mass cytometry time-course data to define eight dis-
tinct EMT–MET states at the single-cell proteomic level; thus,
providing a well-defined EMT–MET state map that discretizes
the EMT spectrum in order to gain an in-depth view of pheno-
typic transitions.
With our single-cell EMT–MET time-course analysis, we
demonstrated not only the heterogeneity of EMT cell states but
also transient properties that provide a deeper appreciation of the
dynamism of EMT. For example, we showed that in NSCLC,
epithelial states can be quite heterogeneous towards E-Cadherin,
CD24, and, interestingly, MUC1 expression. Heterogeneity was
also observed within the pEMT states for various markers, most
notably Twist. Expression of EMT-specific transcription factors
during EMT was recently reported to be dispensable for some
cells, featuring an alternative EMT program that involved protein
internalization43. We observed phenotypically distinct, transient
Twist+ cells that retained some epithelial identity and pro-
liferative capacity, consistent with prior work31. Although tran-
sient Twist activity has been reported26, these prior observations
were made in cells where Twist was exogenously overexpressed;
instead, we examined changes in endogenous Twist during EMT
induction. Twist has been shown to be overexpressed in human
lung adenocarcinoma and specifically correlated to EGFR muta-
tions44, as observed in two of three EGFR-mutated clinical
samples we analyzed (Supplementary Fig. 9). Although we did
not detect other EMT-specific transcription factors (i.e., Slug,
Snail, Zeb1, Fig. 2 and Supplementary Fig. 1), we cannot exclude
the possibility that these may be activated in earlier EMT time-
points not tested here.
Our time-course analysis of MET is a key aspect of our study.
MET is thought to be critical for the establishment of secondary
distant tumors. Yet, compared to EMT, MET is less studied,
particularly with single-cell resolution. Some studies have shown
that EMT is reversible among cells in pEMT states, but not
necessarily among cells that have become mesenchymal, although
this seems to be cell type dependent45,46. Even so, for cells
undergoing MET, it is unclear whether the MET trajectory mir-
rors or differs from the EMT trajectory. Differing trajectories that
we found is evidence of hysteresis, a phenomenon in which a
future state depends on its history. Several mathematical mod-
eling studies have provided evidence of hysteresis when com-
paring EMT and MET; however, these were based on gene
expression or were not associated with specific phenotypic
states29,30. By analyzing time-course data using TRACER, we
found statistically significant evidence of hysteresis. In particular,
we showed that some mesenchymal cells undergo MET utilizing a
trajectory not observed under EMT and transit through a distinct
identified state that we defined as MET. More specifically, our
study supports two possible scenarios. In the first scenario, cells in
the M state have undergone such significant (presumably epige-
netic) changes that in order for some of them to undergo MET,
they utilize a different trajectory. Of note, a significant proportion
of cells failed to undergo MET after 10 days TGFβ withdrawal. It
is possible that if we had prolonged withdrawal, more cells could
have returned to E states, presumably through a combination of
epigenetic/transcriptional mechanisms that regulate phenotypic
switches47. Moreover, we found that if cells have not efficiently
undergone EMT (majority of cells transition to pEMT rather than
M states), most of them are able to undergo MET within 10 days
of TGFβ withdrawal (Supplementary Fig. 7c). This observation is
linked to the second scenario, in which, if during conditions that
promote MET a cell is in a pEMT state, it utilizes a mirrored
trajectory back to an epithelial state. Supporting this, TRACER
detected bi-directionality between pEMT states (Fig. 4e, f).
Notably, TRACER enables the interrogation of the bi-directional
and plastic nature of EMT and MET processes, as opposed to
pseudotime trajectory algorithms (e.g., Wanderlust, Monocle,
Slingshot34,48,49) that are deterministic in nature, forcing the
ordering of transitioning cells on a predefined developmental
path. Specifically, TRACER utilizes the proportion of cells in
each state per time-point to generate a distribution of transition
probabilities, and presents more than one possible EMT trajec-
tories (Fig. 4f). Nevertheless, TRACER’s current limitation is that
Fig. 4 Construction of the EMT–MET PHENOSTAMP and TRACER analysis identify distinct EMT and MET trajectories. a Schematic of 2D t-SNE
EMT–MET PHENOSTAMP. HCC827 CCAST state information was used to determine the highest-density areas of cluster-specific time-dependent bins
and subsequent estimation of respective centers. Compartmentalization was achieved with Voronoi and Convex hull analysis. b Expression profiles of the 6
clustering markers in pooled HCC827 time-point data visualized on the EMT–MET PHENOSTAMP. Dotted circles represent CSC-like (CD44hiCD24lo)
cells. See Supplementary Fig. 7 for remaining markers. c Time-point specific HCC827 t-SNE density plots. d Conceptual model of density plot-inferred EMT
and MET trajectories of transitioning cells (see text for details). Blue arrow depicts the EMT trajectory, whereas red arrows depict two possible MET
trajectories that both may take place depending on conditions; one utilizes the MET state, which supports the notion of hysteresis during MET (red solid
line), and the other utilizes the previously visited pEMT states (red dotted line). e Bootstrap analysis comparing the distribution of time-independent state
transitions as generated by the TRACER algorithm for EMT and MET, represented as box plots, each graph showing transition of a specific state to the all
other states (x-axis). The centers of the box plots represent medians of the bootstrap transition distributions (bootstrap analysis based on n= 10,000 cells
for each of seven measured time-points). The upper (lower) hinge shows the 75th (25th) percentile. The upper (lower) whisker extends from the upper
(lower) hinge to the largest (smallest) value no further than 1.5 times the interquantile range. Box plots color coded as green (left) and yellow (right)
represent EMT and MET, respectively. f Schematic diagram of the TRACER medoid network from bootstrap analysis, depicting transitional probabilities
among states during EMT and MET. Arrows are weighted by probability strength. See Methods for further details. Source Data provided as a Source
Data file.
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it does not account for the expression of intracellular markers
that would offer insights on each state’s cell cycle and death
kinetics, features that could better inform state transitions. Our
data show that M cells express significantly lower levels of the
mitotic marker pH350 compared to MET cells by ~34% (Sup-
plementary Fig. 7 and Supplementary Table 3), suggesting that
our hysteresis findings (M to MET transition) are not due to an
expanding population of cells. Future studies involving live cell
tracing and incorporation of marker expression in our analysis
will be critical towards deciphering EMT–MET dynamics.
We introduce a neural net algorithm for projecting samples on
the EMT–MET PHENOSTAMP with single-cell resolution. This
map can be used as a potential tool to assess NSCLC clinical
specimens in terms of their EMT status, as defined along a well-
established and reproducible in vitro time-course analysis. Our
mapping of five clinical samples serves as proof of concept that
PHENOSTAMP can offer insights on the clinical relevance of of
EMT and MET states. For example, we observed a potential
association of EMT with immune infiltration. Such a correlation
has been previously reported but not linked to mutation status51,
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supporting the necessity of a larger scaled study and the impor-
tance of a well-defined EMT reference map. Furthermore, PHE-
NOSTAMP can help detect EMT-related drug-resistant or
-sensitive cell phenotypes8,52,53 per patient tumor sample. For
instance, studies suggest that inducing MET could be beneficial
by restoring sensitivity to TKI inhibitors16,54. Indeed, our data
showed that pEGFR signaling increased by ~20% in cells
undergoing MET compared to cells in the M state, and this would
hypothetically constitute TKI sensitivity (Supplementary Table 3).
Our data also showed that cells in the MET state significantly
differ from M cells in MUC1 expression, a molecule that is being
studied as a lung cancer therapeutic target55. Therefore,
depending on the situation and timing, one may choose to target
or induce the MET state. Having an EMT–MET map that can
theoretically distinguish whether a specimen has cells undergoing
EMT or MET with targetable markers could benefit such future
efforts.
Our study proposes an approach for interrogating and map-
ping EMT states, but has its limitations. Although here we chose
TGFβ to induce EMT in lung cancer cells, it is well known that
EMT can be triggered by a variety of conditions, including
hypoxia and drug treatments56. It would be therefore reasonable
to compare different modes of EMT induction and examine how
these would affect the EMT–MET map, or the projections onto it.
In addition, incorporating different mutational backgrounds in
our analysis would also be a worthy pursuit. It is important to
note that projecting individual specimens on a reference map
differs from traditional approaches where multiple samples are
pooled for analysis, allowing each specimen to be examined
within its own heterogeneous identity. Also, by using single-cell
proteomic data, our approach differs from similar studies that
have employed basic concepts from machine learning to classify
and diagnose clinical samples based on gene profiling alone36,57.
Functional characterization of each state is also worth pursuing,
given that this would inform each state’s metastatic, drug resis-
tance and stem-like properties. For example, although we used
common markers (CD44hi/CD24lo) for defining CSC-like cells,
we did not functionally test stemness of these cells. In this regard,
it has been shown that CD44hi/CD24hi pEMT cells can exhibit
stem-like behavior11,58. Given that we show that pEMT cells are
plastic in nature (TRACER results), examining the stemness and
drug resistance of the identified pEMT states would be warranted.
Finally, our work can be extended to multiplexed imaging59 to
delineate the spatiotemporal relationships between EMT malig-
nant cell phenotypes and composition of the surrounding
microenvironment.
In summary, we have defined a landscape of EMT and MET
states with single-cell resolution from an in vitro time-course
analysis where we modulated EMT states with TGFβ treatment
and withdrawal. With this information, we created PHENOS-
TAMP that could be used in the future to phenotypically assess
clinical samples. Furthermore, our experimental and computa-
tional approaches provided insights on aspects of EMT basic
biology, EMT/MET trajectories, and the heterogeneity of tran-
sient cell subpopulations undergoing phenotypic transitions.
Combining our work with functional characterization of the
states we have presented here and incorporation of single-cell
data across more patient samples will enable a more a compre-
hensive understanding of the relevance of EMT in cancer.
Methods
Cell culture. HCC827, H3255, and A549 NSCLC adenocarcinoma cell lines were a
generous gift from Dr. Parag Mallick and were grown in RPMI and DMEM
(Dulbecco’s modified Eagle’s medium) media respectively, supplemented with 10%
fetal bovine serum (FBS), and 5% antibiotic solution (penicillin/streptomycin), at
5% CO2 and 37 °C. Cell lines were not tested for mycoplasma contamination or
authenticated for this study.
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cells per clinical sample mapping on the color-coded computationally derived EMT–MET states. See Methods, Supplementary Table 4, and Figs. 9 and 10
for further details.
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EMT induction in NSCLC cell lines. For optimal EMT induction cells were seeded
in 100 mm tissue culture plates at 750,000 cells/plate for 24 h and then switched to
2% FBS media for 24 h. Cells were then treated with 5 ng/mL TGFβ (R&D, #240-B/
CF) for various time-points in 2% FBS media. To keep cell density a non-critical
factor for EMT induction, cells were re-seeded (same number of cells/plate) at each
collection time-point through the entire course of the treatment. For withdrawal
conditions, cells were seeded from TGFβ-treated cells in the absence of ligand and
collected at same time increments as with TGFβ treatments with continuous re-
seeding as mentioned above. In certain cases, TGFβ was added to cells for a period
of 1 or 2 weeks with or without re-seeding as indicated in respective figure legends.
Human studies. Clinical aspects of this study were approved by the Stanford IRB
in accordance with the Declaration of Helsinki guidelines for the ethical conduct of
research. All patients involved provided a written informed consent. Collection and
use of human tissue was approved and was in compliance with data protection
regulations regarding patient confidentiality and were approved under Stanford
IRB protocol #15166. Following surgical resection of primary tumors from five
patients at Stanford hospital, NSCLC adenocarcinoma specimens were immediately
processed in order to achieve single-cell suspensions for mass cytometry analysis.
Immunoblotting. Cells were lysed by adding lysis buffer (50 mM Tris, pH 8.0, 2%
SDS, 1× protease inhibitor cocktail, 25 mM NaF, 100uM Na3VO4, 5 mM EGTA
and 5mM EDTA) to adherent cells (using a cell scraper). Lysates were then
sonicated on ice in order to shear DNA and reduce viscosity. To pellet cellular
debris, lysates were centrifuged at 18,000 × g at 4 °C for 10 min. Protein quantifi-
cation was performed using the Pierce BCA Protein Assay Kit (Thermo Scientific)
and equal amounts of total protein were subjected to standard electrophoresis
conditions. Separated protein lysates were transferred to PVDF membranes (Mil-
lipore #IPVH00010), which were subsequently rinsed in TBST (Tris-buffered sal-
ine, 0.1% Tween-20). Blocking was performed using 5% (w/v) nonfat dry milk in
TBST for 1 h at room temperature, followed by three 5-min washes in TBST.
Membranes were incubated with primary antibody solutions (using 5% milk or
BSA in TBST) overnight at 4 °C at the respective dilutions: E-Cadherin (BD,
#610181, 1:5000), Vimentin (Abcam, ab92547, 1:500), CD44 (CST, #3570, 1:200),
Zeb (CST, #3396, 1:200), Slug (CST, #9585, 1:200), Twist (GeneTex, #GTX127310,
1:500),and GAPDH (CST, #5174, 1:10,000). Membranes were then washed three
times in TBST, 5 min each time, and incubated with appropriate secondary anti-
bodies in blocking solution for 1 h at room temperature. Following three 5-min
washes with TBST, immunoreactivity was visualized using a standard ECL
Detection System. Uncropped/unprocessed scans of all blots shown in the manu-
script are provided in the Source Data file.
Phase-contrast and confocal fluorescence microscopy. Phase-contrast images of
cells undergoing EMT were obtained with a Zeiss Axiovert 40C microscope (×5,
×10, ×20 objectives) equipped with an Axiocam 105 color camera and processed
using the Zen 2 software. For confocal fluorescence microscopy, HCC827 cells that
were previously grown in either control conditions (absence of TGFβ, 2% FBS
RPMI media) or in the presence of TGFβ (5 ng/ml) for a number of days were
seeded on coverslips placed in 6-well plates at a density of 125,000 cells per well.
Treatment with TGFβ was continued depending on time-course requirements.
Following treatment, cells were rinsed with HBSS and subsequently with ice-cold
5% bovine serum albumin/phosphate-buffered saline (BSA/PBS) twice. Cells were
then fixed with paraformaldehyde solution (PFA, EMS, #15710) at a final con-
centration of 4% for 15 min at room temperature, followed by three washes with
PBS. Permeabilization was performed with 0.1% Triton X-100 (Sigma-Aldrich) for
10 min at room temperature, followed by three washes with PBS. Blocking was
performed with 5% BSA/PBS solution for 30 min at room temperature. Cells were
then incubated with fluorophore-conjugated primary antibodies for 1 h in the dark
(Alexa 488 Vimentin antibody (BD, #562338) and Alexa 647 E-Cadherin antibody
(BD, # 324112)). Following three washes with PBS, cells were mounted in Gold
antifade reagent with DAPI (Molecular Probes P36935). Images were obtained and
analyzed using the inverted Zeiss LSM 880 laser scanning confocal microscope with
Airyscan (×40 objective) and Zen Black software, respectively.
Flow cytometry. Following treatments cells were lifted off tissue culture plates
using TrypLE (Life technologies, #12605-010). After counting and assessing %
viability with Trypan Blue exclusion, 1 × 106 cell aliquots per condition were fixed
by adding PFA at a final concentration of 1.6% for 10 min at room temperature.
Cells were then centrifuged at 500 × g for 5 min at 4 °C to pellet cells and remove
PFA and washed once with cell staining media (CSM, 0.5% w/v BSA, 0.02% w/v
NaN3 in PBS). Cells were permeabilized with methanol solution for 10 min on ice
and optionally stored at −80 °C for long-term storage. After two washes with CSM,
master mix of antibodies was added to pelleted cells at a total volume of 100 μL for
30 min in the dark at room temperature. Following two washes with CSM, cells
were analyzed using a LSR II.UV. Cell viability was assessed using the LIVE/DEAD
Fixable Blue Dead Cell Stain Kit (Life Technologies, #L23105) as per the manu-
facturer’s instructions. Fluorophore-conjugated primary antibodies used: PE/Cy7
E-Cadherin (BioLegend, Clone 67A4, #324115), Alexa 488 Vimentin (BD, Clone
RV202, #562338), Pacific Blue CD44 (BioLegend, Clone IM7, #103019), APC/Cy7
CD24 (BioLegend, Clone ML5, #311131), Alexa 647 Twist (Bioss, #bs-2441R). LSR
II. UV was used for analysis and graphs shown were created in Cytobank (www.
cytobank.org, Cytobank Inc., Menlo Park, CA). Flow cytometry and confocal
imaging for this project were performed on instruments in the Stanford Shared
FACS and Cell Sciences Imaging Facilities.
Cell line sample processing for mass cytometry. Cell line samples were pro-
cessed as previously described60. Briefly, following treatments, cells were lifted off
tissue culture plates using TrypLE. Cell count and initial % viability were assessed
using Trypan Blue exclusion. To assess cell viability for mass cytometry, cell pellets
were briefly incubated in 1 mL PBS containing cisplatin (Sigma-Aldrich #P4394,
final concentration 0.5 μM) for 5 min at room temperature. Cisplatin reaction was
quenched by adding complete RPMI media (10% FBS) and subsequent cen-
trifugation for 5 min at 500 × g. Cell pellets were resuspended in cell culture media
(0.5–1 × 106 aliquots per condition) and were fixed by adding PFA at a final
concentration of 1.6% for 10 min at room temperature. Cells were centrifuged at
500 × g for 5 min at 4 °C to pellet cells and remove PFA and washed once with
CSM. Cell pellets were resuspended in CSM and stored at −80 °C until all time-
points of the same time course or multiple clinical specimens were collected.
Tumor dissociation and processing for mass cytometry. Briefly, fresh speci-
mens were immersed and transferred from Stanford Hospital to the laboratory in
MACS Tissue Storage Solution (Miltenyi, #130-095-929). After recording tumor
weight, obtaining macroscopic pictures and removing fat and necrotic areas,
tumors were cut into pieces of 2–4 mm. Tumor dissociation was performed uti-
lizing the MACS Tumor Tissue Dissociation Kit (Miltenyi, #130-095-929) as per
the manufacturer’s instructions. Tumor-derived single-cell suspensions were cen-
trifuged at 500 × g for 5 min to pellet tumor cells, which were subsequently
resuspended in RPMI and applied on a MACS SmartStrainer (70uM, Miltenyi
#130093237) for filtration. Following centrifugation (500 × g, 5 min), red blood
cells were removed using the Red Blood Cell Lysis Solution according to the
manufacturer’s instructions (Miltenyi, #130094183). Tumor cells were then washed
and resuspended in RPMI. Labeling dead cells and subsequent processing of tumor
single-cell suspensions for mass cytometry analysis was performed as described for
cell line samples described above. All samples analyzed were assessed >80% viable
using Trypan Blue prior to fixation.
Mass cytometry antibodies. Antibodies used for mass cytometry analysis,
including respective information on antibody clone, vendor, metal isotope, and
staining concentration, are summarized in Table S1. Aside from one antibody
purchased from Fluidigm (CD104), all antibodies were conjugated to metal iso-
topes in-house using the MaxPar Antibody Conjugation Kit (Fluidigm) and titrated
to determine optimal staining concentrations.
Mass-tag barcoding and antibody staining for mass cytometry. To improve
staining consistency, samples were palladium barcoded and pooled for staining as
previously described61. In short, different combinatorial mixtures of palladium-
containing mass-tag barcoding reagents in dimethyl sulfoxide were added to each
cell line or tumor sample previously resuspended in PBS-saponin solution and
mixed with pipetting. Samples were incubated with barcoding reagents for 15 min
at room temperature. Reaction was quenched with the addition of CSM, followed
by several washes with CSM prior to pooling all samples together to proceed with
staining. Surface and intracellular antigen antibodies were separately added into
two master mixes in CSM, filtered through a 0.1 μm filter (Millipore
#UFC30VV00) and centrifuged at 1000 × g for 5 min to remove antibody aggre-
gates. For tumor specimen analysis, separate staining cocktails using the same
concentrations were prepared with the addition of antibodies towards CD45, FAP,
and CD31 for gating out immune, stromal, and endothelial tumor populations,
respectively, as previously described13. Samples were first incubated with surface
antibody master mix (total volume of 100 μL) for 30 min at room temperature. Cell
samples were then washed with CSM and permeabilized with methanol for 10 min
on ice. Following two washes with CSM, samples were then incubated with the
intracellular antibody master mix (total volume of ~100–150 μL) for 30 min at
room temperature. Samples were washed twice with CSM and resuspended in PBS
containing 1:5000 191Ir/193Ir MaxPar Nucleic Acid Intercalator (Fluidigm) and
1.6% PFA to stain DNA and stored at 4 °C for 1–3 days. Prior to mass cytometry
analysis, cells were washed once with CSM, twice with filtered double-distilled
water, and finally resuspended (~106 stained cells/mL) in filtered double-distilled
water containing normalization beads (EQ Beads, Fluidigm). During event
acquisition, pooled filtered cell samples were kept on ice at all times and introduced
into the CyTOF 2 (Fluidigm) using the Super Sampler (Victorian Airship and
Scientific Apparatus, Alamo, CA, USA). Apart from antibody metal isotopes listed
in Table S1, we also recorded event length, barcoding channels (102Pd, 104Pd,
105Pd, 106Pd, 108Pd, 110Pd), normalization beads (140Ce, 151Eu, 153Eu, 165Ho,
175Lu), DNA (191Ir and 193Ir), and dead cells (195Pt and 196Pt).
Mass cytometry data processing. Normalization and single-cell debarcoding
were performed through respective algorithms as described previously61 and
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transformed using the inverse hyberbolic sine (ArcSinh) function with a cofactor of
552. Debarcoded samples were uploaded as separate FCS files and analyzed on
Cytobank. Non-viable (cisplatin-positive) and apoptotic (cleaved PARP and/or
cleaved Caspase-3) cells were removed for all subsequent single-cell analysis
(Supplementary Fig. 2). Cytobank software was used for traditional cytometry
statistics and visualization (histograms, density plots, heatmaps) and SPADE ana-
lysis62. Briefly, all data presented for NSCLC cell lines and clinical specimens
contained 13,000 to 250,000 and 11,000 to 77,000 viable, non-apoptotic single-cell
events, respectively, per experimental sample. For SPADE analysis of clinical
specimens (Supplementary Fig. 9), downsampled events target was set at 10%, and
the number of nodes target was set at 120. Markers CD45, CD31, FAP, and
cytokeratins 7 and 8 were used for clustering.
CCAST clustering. Raw mass cytometry data from cell line TGFβ time-course
experiments were arsinh transformed on Cytobank. After gating out dead and
apoptotic cells, remaining cells from all time-points were pooled together. The
CCAST-recursive partitioning-based algorithm25 was applied assuming a mini-
mum of eight clusters on a subsample of ~96,000 cells obtained from density-
dependent down sampling62 and based on six EMT clustering markers (E-Cad-
herin, Vimentin, CD44, CD24, MUC1, and Twist). These markers were selected
using an unbiased non-parametric regression tree analysis63. All six markers were
among the most statistically significant markers that correlated independently with
the top three principal components explaining about 50% variability in the data (p
value <0.001, global test of independence constructed by means of the conditional
distribution of linear statistics in the permutation test framework64) (see Supple-
mentary Table S2). Final selection of the six markers was based on EMT biological
relevance. The CCAST analysis resulted initially in 13 clusters (see Supplementary
Fig. 6), of which five were excluded from downstream analysis based on a pre-set
threshold of each cluster ≥1% of total number of cells analyzed. All data processing
and clustering analysis was performed in R.
FDL visualization of CCAST clusters. To visualize the spatiotemporal dynamics
of EMT and MET processes in HCC827 cells treated with TGFβ, we used Vortex, a
graphical tool for visualizing clusters generated from multiparametric datasets.
Specifically, we created single-cell FDLs. The resulting graph was constructed
specifically on the pre-identified eight CCAST clusters. We utilized Vortex to only
implement edge connections between subsequent time-points (similar to the
FLOW-MAP algorithm65). The FDL graph was used to assess the EMT–MET
phenotypic continuum in terms of timing and the expression profiles of all 28
markers measured with mass cytometry. The graph is built by repulsing all cells
with forces proportional to how dissimilar they are in multidimensional protein
expression space, while edges hold adjacent cells together by constant spring-like
forces28.
EMT–MET PHENOSTAMP construction. Using the six CCAST clustering mar-
kers (E-Cadherin, Vimentin, Twist, CD24, CD44, and MUC1), we next generated a
2D t-SNE66 map using the Rtsne package implemented in R with a default per-
plexity parameter of 30. Next, to define regions of the map most uniquely asso-
ciated with each state, we determined the highest-density region per state per
sampling time and estimated its respective centroid. We next applied Voronoi
mapping using eight optimal center points obtained from the above CCAST
clusters. These points were obtained from cluster-specific bins with sizes estimated
by varying sizes of 1 to 8 units over time and selecting the size showing the largest
adjacent change in the number of cells. To place a continuous boundary on the t-
SNE map, we next applied a generalized Convex Hull mapping algorithm, which
combines a Voronoi diagram and Delaunay triangulation67 using the alphahull R
package. The combined t-SNE-Voronoi mapping-Convex Hull analysis produces a
2D EMT–MET state space partition map capturing the plasticity of EMT and MET
processes.
Neural network for projecting onto the EMT–MET PHENOSTAMP. To model
the non-linear structure of the underlying 2D EMT–MET state map, we con-
structed a single-layer-hidden artificial neural network model using the above six
markers as input and the reduced 2D t-SNE feature space as a bivariate response.
Specifically, we used the six input expression values for each cell from the cell line
samples to predict the corresponding position of each new cell onto the 2D
reference map space. Projection results were visualized as bivariate scatter plots. To
train the network, weights on the edges are modified to minimize the error in the
output. At the end of training, the inputs which are most important in prediction
have the largest weights, while those that are less important have lower weights.
The network was trained on 90% min–max normalized data using the “nnet” R
package and the remaining 10% was used (1) to optimize for the 11 hidden nodes
needed and (2) to carry out a 10-fold cross-validation on the stability of model
predictions. The trained neural network was next used to project an independent
HCC827 time-course repeat, A549 and H3255 cell line samples, and five clinical
specimens. A k-nearest neighbor classification on the partition centers was carried
out for each sample to estimate the densities of cells in various EMT state partitions
on the map.
TRACER algorithm. To more rigorously test the hypothesis of hysteresis when
comparing EMT and MET, we developed a trajectory reconstruction analysis TRA-
CER that does not rely on pseudotime assumptions and allows branching. We
assumed that EMT and MET are classical Markov processes35 with constant transi-
tion probabilities between the states within EMT and MET but can differ between
EMT and MET. Because our observations of the proportion of cells in each state are
made at discrete, nonuniform time-points, and because we do not observe the tra-
jectories of individual cells, we cannot employ standard methods to estimate for the
state transition probabilities68. Also, because the number of states is relatively large
compared to the number of observations, we employed sparsity assumptions69. We
modeled the state transition probabilities pjkt between states j and k at time t by
imposing sparsity penalties on pjkt for j not equal to k, but no penalty on pjjt, with the
idea that there is no cost for staying in a state, but switching between states is
discouraged. Under these assumptions, the transition probabilities EMT and MET can
be estimated by convex optimization, with the sparsity parameter λ selected through
cross-validation. We chose by the 1-standard error rule70, that is, we chose the largest
λ such that its error is within 1-standard error of the error of the minimizing. This
leads to a more parsimonious solution. Using bootstrap analysis, we provide a dis-
tribution of the transition probabilities for EMT and MET, as shown in Fig. 4e. For
the bootstrap analysis, we first independently sampled a multinomial distribution for
cell counts in each state. We split the bootstrap sample into 2-folds. The first fold was
used to estimate the sparsity parameter λ. We evaluated the estimator with the chosen
λ on the second fold. For representative EMT and MET networks, the medoid
networks for EMT and MET was selected among all the bootstrap samples as the
network for which the average distance to all other networks (entry-wise L1 distance
between transition matrices) was smallest (Fig. 4f).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The mass cytometry time-series data have been deposited in the Cytobank Stanford
database under the name “Karacosta et al. HCC827 EMT time-series mass cytometry
data” [https://stanford.cytobank.org/cytobank/experiments/26555]. All the other data
supporting the findings of this study are available within the article and
its Supplementary Information files and from the corresponding author upon reasonable
request. A reporting summary for this article is available as a Supplementary Information
file. The source data underlying Figs. 1a, e, 3b, c, 4e and Supplementary Fig. 1g are
provided as a Source Data file and these include all raw single-cell data resulting from the
CCAST analysis described in the paper.
Code availability
PHENOSTAMP and TRACER codes used for the construction of the EMT–MET
PHENOSTAMP and projections and the interrogation of EMT–MET trajectories,
respectively, have been deposited on GitHub under [https://github.com/anchangben/
PHENOSTAMP] and [https://github.com/nignatiadis/TRACER] and are available to the
public. PHENOSTAMP relies on R (≥3.5.0) and other R libraries. The implementation
provided on the github link runs on Mac OS X 10.7 and above operating systems. The
TRACER algorithm has been implemented as a R package (R version 3.6.1), which uses
the tidyverse (version 1.2.1), ggplot2 (version 3.2.1), and JuliaCall71 (version 0.16.6)
packages. The optimization problem is solved in Julia (version 1.2) through the JuMP.jl72
(version 0.18.6) and Gurobi.jl (version 0.7.2) packages by interfacing to the Gurobi
optimizer (version 8.1.0).
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